LSX Investival Showcase London 2026
LSX Investival Showcase London is a one-day life science partnering and investment conference run by Informa Connect. It connects biopharma and medtech executives with investors and strategic partners, and the organizer places it on the first day of London Life Science Week.
Monday
Old Billingsgate
Organizer
Not published
Exhibitor list
Every year
How often it's held
Checked October 20, 2026
Reported attendance
1,000+
attendees · year not stated
Reported exhibitors
Not published
About LSX Investival Showcase London 2026
LSX Investival Showcase London is a one-day life science partnering and investment event run by Informa Connect. It connects biotech, medtech and healthtech companies with investors and pharma partners. The next edition runs on Monday 16 November 2026 at Old Billingsgate in London. The organizer lists 1,000+ attendees, 400+ investors and strategics and 150+ company showcases without giving a year. It says the event takes place on the first day of London Life Science Week.
400+
Investors and strategics
150+
Company showcases
2,000+
One-to-one partnering meetings
7
Stages
What happens at LSX Investival Showcase London
The day mixes company pitches, investor panels and one-to-one partnering. The 2026 agenda runs across seven stages at Old Billingsgate. They're the Headliner Stage, the Masterclass Stage, two Biotech Startup Showcase stages and the Biotech Growth, Medtech and TechBio and Digital showcase stages.
Headliner panels on the 2026 agenda cover biopharma M&A, licensing deals with China and US market entry. Later panels look at women's health, AI, philanthropic capital and the UK as a life science hub. The Masterclass Stage holds sessions on IP, licensing, IPOs, M&A and fundraising.
Company showcases are 15-minute presentations to investors and partners. Partnering runs on partneringONE, where attendees see who else is coming and request meetings. Partnering meetings last 25 minutes, and the official floor plan puts the partnering area on the lower level. It's a form of one-to-one meetings arranged before the event.
The agenda opens with an optional 4.9 km sunrise run and closes with a networking drinks reception. In the evening, the ticketed European Lifestars Awards gala dinner follows. Attendees get a reduced rate when they add the awards dinner to their booking. Before the event, the organizer ran a US IPO webinar on 13 October 2026.
Who attends LSX Investival Showcase London
The event draws life science companies, investors and pharma partners. The organizer's sponsorship page names emerging biotech, medtech and healthtech companies, life science VCs, corporate venture arms, angels and family offices. It also lists pharma companies seeking partners, licensing executives and technology transfer staff from universities.
- UK & Ireland45%
- Europe33%
- North America11%
- Nordics7%
- Other4%
From the organizer's Attending Investor Summary headed 16 November 2026. The document doesn't say when or how investors were counted.informaconnect.com ↗
- Venture Capital66%
- Corporate / Strategic VC12%
- Family Office8%
- Private Equity4%
- Institutional3%
- Other3%
- Debt Finance2%
- Fund2%
From the organizer's Attending Investor Summary headed 16 November 2026. The document doesn't say when or how investors were counted.informaconnect.com ↗
The organizer's Attending Investor Summary for the 2026 edition breaks down investors by location and type. UK and Ireland investors make up 45%, other European investors 33% and North American investors 11%. Venture capital firms account for 66% of investors, corporate or strategic VCs 12% and family offices 8%. The document doesn't say when or how the investors were counted.
Investors register under the organizer's investor qualification criteria. They cover funds, pension plans, family offices, angel groups, foundations and VC or PE firms managing $25 million or more. Service providers, bankers, crowdfunding platforms and individual angels don't qualify for the investor route.
Past investors named on the investor attendees page include Abingworth, Forbion, Gilde Healthcare, Johnson & Johnson and Medicxi. Novo Seeds, Sofinnova Partners, Syncona, RTW Investments, BlackRock and SoftBank are also listed. The page doesn't say which editions they attended.
Attendance and exhibitors by year
As the organizer reports them. What's counted varies between events, so compare with care.
| Edition | Attendance |
|---|---|
| Not stated | 1,000+attendeesThe organizer's site gives this figure without a year.informaconnect.com ↗ |
Companies speaking and presenting at LSX Investival Showcase London 2026
Investors, pharma deal makers, advisers and young companies make up the 2026 program. Pharma and corporate investors on the 2026 agenda include GSK, Novartis Venture Fund, Novo Holdings, Sanofi Ventures and Chiesi Group. Venture investors include Forbion, Sofinnova Partners, Medicxi, JEITO, Earlybird and Gilde Healthcare.
Sponsors (21)Winston Taylor, Baker McKenzie, CFGI and 18 more
- Winston Taylor · 2026Platinum sponsor
- Baker McKenzie · 2026Gold sponsor
- CFGI · 2026Gold sponsor
- Goodwin Procter · 2026Gold sponsor
- HSBC · 2026Gold sponsor
- Insmed · 2026Gold sponsor
- Latham & Watkins · 2026Gold sponsor
- Leerink Partners · 2026Gold sponsor
- Merck KGaA · 2026Gold sponsor
- Mintz · 2026Gold sponsor
- Skadden · 2026Gold sponsor
- A&O Shearman · 2026Silver sponsor
- Bayer Co.Lab · 2026Silver sponsor
- Orrick · 2026Silver sponsor
- Osborne Clarke · 2026Silver sponsor
- Prudentia Sciences · 2026Silver sponsor
- Stout Risius Ross, LLC · 2026Silver sponsor
- TTP Plc · 2026Silver sponsor
- Business France · 2026Bronze sponsor
- Citi Bank · 2026Bronze sponsor
- Donnelley Financial Solutions · 2026Bronze sponsor
Partners (30)BioXconomy, European Lifestars Awards, Life Science Accounting & Reporting Europe and 27 more
- BioXconomy · 2026Lead media partner
- European Lifestars Awards · 2026Supporting event
- Life Science Accounting & Reporting Europe · 2026Supporting event
- London Life Sciences Week · 2026Supporting event
- ABHI · 2026Supporting partner
- Argentum · 2026Supporting partner
- BioM · 2026Supporting partner
- BioPartner UK · 2026Supporting partner
- BioPharma Asia · 2026Supporting partner
- BIOTECanada · 2026Supporting partner
- Codon Communications · 2026Supporting partner
- Digital Health and Care Alliance (DHACA) · 2026Supporting partner
- Drug Discovery & Development · 2026Supporting partner
- European Healthcare Investor Association · 2026Supporting partner
- Freemind · 2026Supporting partner
- Health Wildcatters · 2026Supporting partner
- Hollandbio · 2026Supporting partner
- Japan Bioindustry Association (JBA) · 2026Supporting partner
- Life Science British Columbia · 2026Supporting partner
- Medicon Valley Alliance · 2026Supporting partner
- MedNous · 2026Supporting partner
- One Nucleus · 2026Supporting partner
- Pharma Press Global · 2026Supporting partner
- Scius Communications · 2026Supporting partner
- Society of Physician Entrepreneurs · 2026Supporting partner
- Star Tree Ventures · 2026Supporting partner
- SwedenBIO · 2026Supporting partner
- UK BioIndustry Association · 2026Supporting partner
- Venture Valuation · 2026Supporting partner
- Zyme Communications · 2026Supporting partner
Speakers' companies (39)Theolytics, Pathios Therapeutics, RegenSight and 36 more
- Theolytics · 2026Company showcase presentation
- Pathios Therapeutics · 2026Company showcase presentation
- RegenSight · 2026Company showcase presentation
- Rakuten Medical · 2026Company showcase presentation
- TheraCryf · 2026Company showcase presentation
- Korecyte Bio · 2026Company showcase presentation
- Nanoncolytics · 2026Company showcase presentation
- Ksilink · 2026Company showcase presentation
- EnsiliTech · 2026Company showcase presentation
- ReNewVax · 2026Company showcase presentation
- kez.biosolutions · 2026Company showcase presentation
- Bactheravax · 2026Company showcase presentation
- Ageless Bio · 2026Company showcase presentation
- Nodal Therapeutics · 2026Company showcase presentation
- Lentitek · 2026Company showcase presentation
- Nebu-Flow · 2026Company showcase presentation
- Idevax · 2026Company showcase presentation
- NeoCare Nordic · 2026Company showcase presentation
- WhiteLab Genomics · 2026Company showcase presentation
- Cytocast · 2026Company showcase presentation
- Noga Therapeutics · 2026Company showcase presentation
- Cogmotiv · 2026Company showcase presentation
- GSK · 2026Jon Kiburz and Austin Doyle speak on the M&A and China licensing panels.
- Novartis Venture Fund · 2026Anja König speaks on the opening keynote panel.
- Novo Holdings · 2026Michael Bauer speaks on the biopharma M&A panel.
- Chiesi Group · 2026Stefano Cottignoli speaks on the biopharma M&A panel.
- Sanofi Ventures · 2026Partner Laia Crespo is on the agenda.
- Abingworth · 2026Tim Haines speaks on the opening keynote panel.
- Angelini Ventures · 2026Paolo Di Giorgio speaks on the opening keynote panel.
- BNP Paribas Asset Management · 2026Zina Affas Besse speaks on the opening keynote panel.
- Sofinnova Partners · 2026Anta Gkelou speaks on the opening keynote panel.
- Forbion · 2026Mathias Vinther speaks on the US market entry panel.
- Medicxi · 2026Giovanni Mariggi speaks on the biopharma M&A panel.
- Gilde Healthcare · 2026Janke Dittmer speaks on the US market entry panel.
- JEITO · 2026Magdalena Jonikas and Anastasiya Sybirna speak on headliner panels.
- Insilico Medicine · 2026Jue Wang speaks on the AI panel.
- Flagship Pioneering · 2026Lena Afeyan speaks on the UK panel.
- British Business Bank · 2026Mark Andrews speaks on the UK panel.
- Cancer Research Horizons · 2026Tanya Moore and Torquil Jackson speak on headliner panels.
Attending (7)Johnson & Johnson, Novo Seeds, Syncona and 4 more
- Johnson & JohnsonNamed among past investors, editions not given
- Novo SeedsNamed among past investors, editions not given
- SynconaNamed among past investors, editions not given
- RTW InvestmentsNamed among past investors, editions not given
- EQT Life SciencesNamed among past investors, editions not given
- BlackRockNamed among past investors, editions not given
- SoftBankNamed among past investors, editions not given
Start-ups and growth companies pitch in company showcases on five showcase stages. The companies below are on the 2026 agenda with a showcase slot. For other life science partnering events, see BIO-Europe Spring 2027 and Biotech Showcase 2027.
Exhibiting and presenting at LSX Investival Showcase London
There's no exhibition hall or booth list. Companies present on stage and meet in partnering instead. The official 2026 floor plan shows the stages on the ground floor and the partnering area below. A lounge with sponsor meeting rooms sits on the floor above.
The showcase package costs £2,765 plus 20% VAT. It includes two partnering tickets and a 15-minute presentation on a suitable stage. It's for biotech, pharma, drug delivery, diagnostics, medical device, healthtech and techbio companies developing their own products.
The showcase page says all Startup Showcase slots are sold out. Slots remain on the Biotech Growth, Medtech and TechBio and Digital stages. The organizer vets each registration against its criteria.
Presenters and sponsors book meetings through partneringONE. Teams comparing tools can read our guide to meeting scheduling software.
Sponsors and partners at LSX Investival Showcase London 2026
The 2026 sponsor list has 21 sponsors in four tiers. Winston Taylor is the Platinum sponsor. The ten Gold sponsors are Baker McKenzie, CFGI, Goodwin Procter, HSBC, Insmed, Latham & Watkins, Leerink Partners, Merck KGaA, Mintz and Skadden.
Silver sponsors are A&O Shearman, Bayer Co.Lab, Orrick, Osborne Clarke, Prudentia Sciences, Stout and TTP. Bronze sponsors are Business France, Citi Bank and Donnelley Financial Solutions.
The supporting partners page lists BioXconomy as lead media partner and 26 supporting partners. They include the UK BioIndustry Association, One Nucleus, ABHI, BioM, Hollandbio, SwedenBIO and Medicon Valley Alliance.
Sponsorship is sold as a custom package. The sponsorship options page promises pipeline, visibility and expert positioning, and points to a brochure behind a request form. Many sponsors also place a speaker on a panel. Our roundup of sponsorship management software covers tools for running these deals.
- Winston Taylor, Platinum sponsor in 2026. The organizer's profile calls it a transatlantic law firm. Partner Ross McNaughton speaks on the medtech and biotech investing panel.
- Baker McKenzie, Gold sponsor in 2026.
- CFGI, Gold sponsor in 2026. Its profile describes an accounting and business advisory firm.
- Goodwin Procter, Gold sponsor in 2026.
- HSBC, Gold sponsor in 2026. HSBC Innovation Banking's Jamie Bignal speaks on the UK panel.
- Insmed, Gold sponsor in 2026. Its profile describes a global biopharmaceutical company. Philip Coxon speaks on the China licensing panel.
- Latham & Watkins, Gold sponsor in 2026. Partner Lydia Torne speaks on the China licensing panel.
- Leerink Partners, Gold sponsor in 2026. Eric Stewart speaks on the biopharma M&A panel.
- Merck KGaA, Gold sponsor in 2026.
- Mintz, Gold sponsor in 2026. John Rudy speaks on the US market entry panel.
- Skadden, Gold sponsor in 2026. Partner Dohyun Kim speaks on the biopharma M&A panel.
- A&O Shearman, Silver sponsor in 2026. Megan McMellon speaks on the AI panel.
- Bayer Co.Lab, Silver sponsor in 2026. Its profile describes Bayer's incubator network for early-stage life science ventures. It runs a masterclass on its Berlin program.
- Orrick, Silver sponsor in 2026.
- Osborne Clarke, Silver sponsor in 2026. Partner Matthew Edwards speaks on the opening keynote panel.
- Prudentia Sciences, Silver sponsor in 2026. Its profile describes AI-powered technology for investment in new therapies.
- Stout Risius Ross, LLC, Silver sponsor in 2026. Its profile describes a global advisory firm. Kelly Provost speaks on the US market entry panel.
- TTP Plc, Silver sponsor in 2026. Stuart Lowe speaks on the opening keynote panel.
- Business France, Bronze sponsor in 2026.
- Citi Bank, Bronze sponsor in 2026.
- Donnelley Financial Solutions, Bronze sponsor in 2026.
The event's tech
We couldn't identify a third-party registration platform on the event's website.
LSX Investival Showcase London attendee list, exhibitor list and sponsor list
Exhibitor list
Not published
Sponsor list
Published
Attendee list
Not published or sold
There's no exhibitor list because the event has no booths. The official sponsor and partner list is public on the event site. The 2026 agenda names every company showcase by stage and time slot.
The organizer offers a 2026 attendee list download behind a contact form. Registered delegates can see other attendees inside partneringONE. The paid partneringONE plus upgrade includes access to the event registration list and shows registrations right away. Other delegates wait until four to six weeks before the event.
The organizer warns that outside vendors selling attendee lists work without its approval. It also says it doesn't use a third-party hotel booking agency for the event.
For more on this, see how to find who's attending an event and our list of event intelligence platforms.
See who's attending LSX Investival Showcase London
Organizers don't publish attendee lists. These event intelligence platforms show which companies and roles are likely to attend and help you book meetings. How to find who's attending
Speakers at LSX Investival Showcase London 2026
The 2026 speaker list names investors, pharma deal makers, advisers and company founders. Our count of that page on 20 October 2026 found 182 speakers.
- Tim HainesExecutive Partner, AbingworthKeynote · Opening Keynote Panel: Who Controls the Pace? Europe's Response to Global Competition · 2026
- Anja KönigGlobal Head, Novartis Venture FundKeynote · Opening Keynote Panel: Who Controls the Pace? Europe's Response to Global Competition · 2026
- Paolo Di GiorgioCEO & Managing Director, Angelini VenturesKeynote · Opening Keynote Panel: Who Controls the Pace? Europe's Response to Global Competition · 2026
- Zina Affas BessePartner & Deputy Head of Healthcare Private Equity, BNP Paribas Asset ManagementKeynote · Opening Keynote Panel: Who Controls the Pace? Europe's Response to Global Competition · 2026
- Anta GkelouPartner, Sofinnova PartnersKeynote · Opening Keynote Panel: Who Controls the Pace? Europe's Response to Global Competition · 2026
- Stuart LoweHead of Advanced Therapies, TTPKeynote · Opening Keynote Panel: Who Controls the Pace? Europe's Response to Global Competition · 2026
- Matthew EdwardsPartner, Osborne ClarkeKeynote · Opening Keynote Panel: Who Controls the Pace? Europe's Response to Global Competition · 2026
More speakers (53)Jon Kiburz, Michael Bauer, Giovanni Mariggi and 50 more
- Jon KiburzVP, Business Development Transactions, GSKPanelist · 2026 and BioPharma's M&A Boom · 2026
- Michael BauerPartner, Novo HoldingsPanelist · 2026 and BioPharma's M&A Boom · 2026
- Giovanni MariggiPartner, MedicxiPanelist · 2026 and BioPharma's M&A Boom · 2026
- Stefano CottignoliSVP, Head of Global Business and Corporate Development, Chiesi GroupPanelist · 2026 and BioPharma's M&A Boom · 2026
- Eric StewartSenior Managing Director, Healthcare Mergers & Acquisitions, LeerinkPanelist · 2026 and BioPharma's M&A Boom · 2026
- Dohyun KimPartner, SkaddenPanelist · 2026 and BioPharma's M&A Boom · 2026
- Sadiqa MahmoodFounder & CEO, Prudentia SciencesPanelist · Breaking Barriers: Cross-Border Licensing and Deal-Making in China · 2026
- Debra YuCOO & Partner, Panacea CapitalPanelist · Breaking Barriers: Cross-Border Licensing and Deal-Making in China · 2026
- Wei PengCo-Founder & Chief Business Officer, Crimson GatewayPanelist · Breaking Barriers: Cross-Border Licensing and Deal-Making in China · 2026
- Philip CoxonExecutive Director, Business Development, InsmedPanelist · Breaking Barriers: Cross-Border Licensing and Deal-Making in China · 2026
- Lydia TornePartner, Latham & WatkinsPanelist · Breaking Barriers: Cross-Border Licensing and Deal-Making in China · 2026
- Austin DoyleExecutive Director, Business Development Transactions, GSKPanelist · Breaking Barriers: Cross-Border Licensing and Deal-Making in China · 2026
- Kelly ProvostManaging Director, Accounting & Reporting Advisory, StoutModerator · From Vision to Reality: US Market Entry and Public Market Pathways · 2026
- Maha RadhakrishnanExecutive Partner, Sofinnova InvestmentsPanelist · From Vision to Reality: US Market Entry and Public Market Pathways · 2026
- Mathias VintherPartner, ForbionPanelist · From Vision to Reality: US Market Entry and Public Market Pathways · 2026
- Janke DittmerGeneral Partner, Head of European HealthTech Investments, Gilde HealthcarePanelist · From Vision to Reality: US Market Entry and Public Market Pathways · 2026
- John RudyMember / Co-chair, Securities & Capital Markets Practice, MintzPanelist · From Vision to Reality: US Market Entry and Public Market Pathways · 2026
- Magdalena JonikasPartner, JEITOPanelist · From Vision to Reality: US Market Entry and Public Market Pathways · 2026
- Millie NelsonSenior Editor, Partnering & Investment, BioXconomyPanelist · Scaling Women's Health: Investment, Consolidation, and the Path Forward · 2026
- Melissa SimonPartner, Wieland CapitalPanelist · Scaling Women's Health: Investment, Consolidation, and the Path Forward · 2026
- Mohammad KhobrehManaging Partner, NG BioPanelist · Scaling Women's Health: Investment, Consolidation, and the Path Forward · 2026
- Agnès ArbatCEO, Oriva TherapeuticsPanelist · Scaling Women's Health: Investment, Consolidation, and the Path Forward · 2026
- Oliver LythAssociate, M VenturesPanelist · Scaling Women's Health: Investment, Consolidation, and the Path Forward · 2026
- Anastasiya SybirnaPrincipal, JEITOPanelist · Scaling Women's Health: Investment, Consolidation, and the Path Forward · 2026
- Megan McMellonSenior Associate, Commercial IP, A&O ShearmanPanelist · Where Has AI Been Most Effective in Life Sciences? Lessons Learned and the Path Forward · 2026
- Carl FirthPartner, Panacea CapitalPanelist · Where Has AI Been Most Effective in Life Sciences? Lessons Learned and the Path Forward · 2026
- Piotr SurmaCEO, IngenixPanelist · Where Has AI Been Most Effective in Life Sciences? Lessons Learned and the Path Forward · 2026
- Jue WangVP, Global Head of Business Development, Insilico MedicinePanelist · Where Has AI Been Most Effective in Life Sciences? Lessons Learned and the Path Forward · 2026
- Winston HaynesVP Computational Sciences and Engineering, LabGenius TherapeuticsPanelist · Where Has AI Been Most Effective in Life Sciences? Lessons Learned and the Path Forward · 2026
- Ross McNaughtonPartner, Winston TaylorPanelist · Investing Across MedTech & Biotech: Decoding Investor Appetite and Risk Perception · 2026
- Jennifer McMahonPartner, Seroba Life SciencesPanelist · Investing Across MedTech & Biotech: Decoding Investor Appetite and Risk Perception · 2026
- Laurent PachecoCEO, International Family Offices Alliance for HealthPanelist · Investing Across MedTech & Biotech: Decoding Investor Appetite and Risk Perception · 2026
- Dominik LeisiInvestment Manager, Atlantic BridgePanelist · Investing Across MedTech & Biotech: Decoding Investor Appetite and Risk Perception · 2026
- Yara AlenaziInvestor, Crane Venture PartnersPanelist · Investing Across MedTech & Biotech: Decoding Investor Appetite and Risk Perception · 2026
- Tanya MooreInvestment Principal, Ventures, Cancer Research HorizonsPanelist · Investing Across MedTech & Biotech: Decoding Investor Appetite and Risk Perception · 2026
- Torquil JacksonInvestment Manager, Cancer Research HorizonsPanelist · Philanthropic Capital: Life Science's Untapped Opportunity · 2026
- Everett KaminChief Investment Officer, Gemini Capital PartnersPanelist · Philanthropic Capital: Life Science's Untapped Opportunity · 2026
- Felix LitzkowHead of Macmillan Ventures, Macmillan Cancer SupportPanelist · Philanthropic Capital: Life Science's Untapped Opportunity · 2026
- Robert SmithFounder & CEO, Conscious CapitalPanelist · Philanthropic Capital: Life Science's Untapped Opportunity · 2026
- Colleen AcostaCo-Founder & CEO, Freya BiosciencesPanelist · Philanthropic Capital: Life Science's Untapped Opportunity · 2026
- Jamie BignalDirector, HSBC Innovation BankingPanelist · UK Calling: Is Britain Still an Attractive Hub for Life Science Companies? · 2026
- Sam GrayManaging Partner, Apposite CapitalPanelist · UK Calling: Is Britain Still an Attractive Hub for Life Science Companies? · 2026
- Kristin-Anne RutterExecutive Director, Cambridge University Health PartnersPanelist · UK Calling: Is Britain Still an Attractive Hub for Life Science Companies? · 2026
- Lena AfeyanHead of UK Science Strategy and Innovation, Flagship PioneeringPanelist · UK Calling: Is Britain Still an Attractive Hub for Life Science Companies? · 2026
- Mark AndrewsInvestment Director, Life Sciences, British Business BankPanelist · UK Calling: Is Britain Still an Attractive Hub for Life Science Companies? · 2026
- Chris MolloyCEO, BioIndustry Association (BIA)Panelist · UK Calling: Is Britain Still an Attractive Hub for Life Science Companies? · 2026
- Ruth ShahHead of Bayer Co.Lab Berlin, BayerWorking with Bayer Co.Lab Berlin – Building the Next Gen of Biotech's · 2026
- Olga DanilchankaPartner, MRL Ventures Fund, MerckPanelist · Seed Funding Essentials: What Early-Stage Biotech Investors Actually Want · 2026
- Laura RodriguezPartner, Invivo CapitalPanelist · Seed Funding Essentials: What Early-Stage Biotech Investors Actually Want · 2026
- Giulia VestriPartner, Claris VenturesPanelist · Seed Funding Essentials: What Early-Stage Biotech Investors Actually Want · 2026
- Thom RascheManaging Partner, EarlybirdPanelist · Capital Allocation in Medtech: What VCs Are Backing & Why · 2026
- Caroline GaynorPartner, Lightstone VenturesPanelist · Capital Allocation in Medtech: What VCs Are Backing & Why · 2026
- Jan EngelsSenior Investment Manager, High-Tech GründerfondsPanelist · Capital Allocation in Medtech: What VCs Are Backing & Why · 2026
The opening keynote panel asks how Europe can keep pace with the US and China. It features Tim Haines of Abingworth, Anja König of Novartis Venture Fund and Paolo Di Giorgio of Angelini Ventures. Zina Affas Besse of BNP Paribas Asset Management and Anta Gkelou of Sofinnova Partners join them.
Jon Kiburz of GSK, Michael Bauer of Novo Holdings and Giovanni Mariggi of Medicxi speak on the biopharma M&A panel. Mintz says its partner John Rudy speaks on the US market entry panel, which Stout's Kelly Provost moderates.
Investors can also take part as expert feedback panelists or in the main agenda, according to the investor registration page.
Dates, venue and getting there
The 2026 edition runs on Monday 16 November 2026 at Old Billingsgate in the City of London. Old Billingsgate is a Grade II listed former fish market on the north bank of the Thames. Its address is 1 Old Billingsgate Walk, London EC3R 6DX.
Registration and breakfast open at 8 a.m., and the closing drinks reception starts at 5 p.m. The European Lifestars gala dinner follows at a separate venue.
Monument station is about four minutes' walk away and Bank about nine minutes, per the venue and travel page. There's no parking on site. London City Airport is 8.4 miles away.
RSM, a sponsor of the wider week, says London Life Sciences Week runs from 15 to 20 November 2026. The organizer places the showcase on the first day of that week.
- Lounge, catering and sponsor meeting rooms (Level 1)
- Stage floor (Level 0)
- Headliner, Masterclass and showcase stages
- Partnering area, partneringONE (Level -1)
- Registration and service areas
Simplified from the organizer's three-level plan of Old Billingsgate. The partnering level has numbered meeting spots from 1 to 117.
Tickets and registration for LSX Investival Showcase London
Prices below come from the organizer's booking pages, checked in October 2026. They exclude 20% UK VAT.
A partnering ticket for life science companies costs £1,315. Professional, financial and contract services firms pay £1,420 for theirs. A qualified investor partnering ticket costs £520.
The standard ticket without partnering costs £1,045. It covers sessions and networking but not the partnering platform.
Full-time academics can apply for 50% off. Groups of three or four save 20%, and groups of five or more save 30%. Journalists from sector media can apply for a free press pass.
Investors must meet the qualification criteria. An investor who gets complimentary registration must hold at least two partnering meetings.
History of LSX Investival Showcase London
The organizer marks 2026 as 11 years of life science partnering at the Investival Showcase London. The event belongs to Informa Connect's LSX series. Its partnering team sits with EBD Group, which runs partneringONE for the event.
Resources for exhibitors, sponsors and attendees
These official pages cover registration, partnering, sponsorship and travel.
- Registration optionsCompares the premium, showcase, investor, standard and press passes.
- Ticket booking pageLists partnering ticket prices by company type.
- Investor qualification criteriaExplain who can use the investor route.
- 2026 agendaLists every session and company showcase by stage.
- Speaker listShows the 2026 speakers and their companies.
- Partnering FAQsExplain meeting length, schedules and rescheduling.
- Sponsors and partnersShows the 2026 sponsors by tier.
- Sponsorship optionsDescribe what sponsors get and how to ask for the brochure.
- Floor planShows the three levels of Old Billingsgate.
- Venue and travelCovers the address, Tube stations, parking and airports.
- HotelsMaps hotels near the venue.
- Attending Investor SummaryGives the investor breakdowns published for 2026.